



PATENT
Present Attorney Docket No. 05237.0003.CPUS01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Link et al.

Serial No.: 09/811,842

Filed: March 19, 2001

For: Methods and Compositions for
Elucidating Protein Expression
Profiles in Cells

Group Art Unit: 1636

Examiner: David A. Lambertson

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number

EV 023934981 US

Date of Deposit October 14, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

Nate Le

(Typed or printed name of person mailing)

(Signature of person mailing)

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 and 1.98**

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, the applicants call to the attention of the examiner references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. The applicants submit copies for all the references, except for references B1, C4, C31 and C32 which are not readily available to us.

This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes art under 35 U.S.C. §102 or §103.

The Information Disclosure Statement accompanies the Request for Continued Examination. Consequently, pursuant to 37 C.F.R. § 1.97 (b) (4), we do not believe any fee is due with the submission of this Information Disclosure Statement. However, should any fees be

Application No. 09/811,842
Filed: March 19, 2001
Page 2

Docket No. 05237.0003.CPUS01

deemed necessary in connection with the filing of this document, the Commissioner is hereby authorized to deduct any such fees from our Deposit Account No. 08-3038.

Respectfully submitted,


HOWREY SIMON ARNOLD & WHITE, LLP

By: 

David W. Clough, Ph.D.

Registration No.: 36,107

Dated: October 14, 2003
321 N. Clark Street, Suite 3400
Chicago, IL 60610
Telephone: (312) 595-1408
Fax: (312) 595-2250



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/811,842
		Filing Date	March 19, 2001
		First Named Inventor	Charles Link
		Group Art Unit	1636
		Examiner Name	David Lambertson
Attorney Docket Number	05237.0003.000000		
Sheet	1	of	5

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A1	US-4,683,195	07-28-1987	Mullis	
	A2	US-5,364,783	11-15-1994	Ruley	
	A3	US-5,565,350	05-05-1998	Kmiec et al.	
	A4	US-5,922,601	07-13-1999	Baetscher	
	A5	US-6,130,313	10-10-2000	Li	
	A6	US-5,928,888	07-27-1999	Whitney	
	A7	2002/0025940 A1	02-28-2002	Whitney	
	A8	US-6,096,717	08-01-2000	Jarvik	
	A9	US-6,498,013 B1	12-24-2002	Velculescu	
	A10	US-6,080,576	06-27-2000	Zambrowicz	


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)				
	B1	PCT/US93/03868		Zarling et al.		
	B2	WO 98/53319	11-26-98	Vogelstein		
	B3	WO 99/02719	01-21-99	Christopher		

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/811,824		
		Filing Date	March 19, 2003		
		First Named Inventor	Charles Link		
		Group Art Unit	1636		
		Examiner Name	David A. Lambertson		
Sheet	2	of	5	Attorney Docket Number	05237.0003.000000


OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	C1	Altschul et al. (1997). Nucleic Acids Res. 25: 3389-3402	
	C2	Armentano et al. (1987). J. Virol. 61: 1647-1650	
	C3	Bender et al. (1987). J Virol. 61: 1639-1649	
	C4	Chang et al. (1977). Nature 198: 1056	
	C5	Claverie and States (1993). Comput. Chem. 17: 191-201	
	C6	Cormier et al. (1974). Bioluminescence in Coelenterates. Biochem. Biophys. Acta 346: 137-164	
	C7	Corpet et al. (1988). Nucleic Acid Res. 16: 10881-90	
	C8	Costa et al. (1998). Transcriptional regulation of the tissue-type plasminogen activator gene in human endothelial cells: identification of nuclear factors that recognize functional elements in the tissue-type plasminogen activator gene promoter. European Journal of Biochemistry 258: 123-131	
	C9	Cytometry (1996). 23: 46	
	C10	Henikoff and Henikoff (1992). Proc. Natl. Acad. Sci. USA 89: 10915	
	C11	Higgins and Sharp (1988). Gene 73: 237-244	
	C12	Higgins and Sharp (1989). CABIOS 5: 151-153	
	C13	The human gene consortium. (2001). Nature 409: 860-921	
	C14	Huang et al. (1992). Computer Applications in the Biosciences 8: 155-65	
	C15	Fassati et al. (1998). Insertion of Two Independent Enhancers in the Long Terminal Repeat of a Self Inactivating Vector Results in High-Titer Retroviral Vectors With Tissue Specific Expression. Human Gene Therapy 9: 2459-2468	
	C16	Fleischmann et al. (1998). Cardiac Specific Expression of the Green Fluorescent Protein During Early Murine Embryonic Development. FEBS Letters 440: 370-376	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/811,824
		Filing Date	March 19, 2003
		First Named Inventor	Charles Link
		Group Art Unit	1636
		Examiner Name	David A. Lambertson
		Attorney Docket Number	05237.0003.000000
Sheet	3	of	5

C17	Fraser et al. (1997). Strategies for whole microbial genome sequencing and analysis. Electrophoresis 18: 1207-1216	
C18	Goeddel et al. (1980). Nucleic Acid Res. 8: 4057	
C19	Gygi et al. (1999). Correlation between protein and mRNA abundance in yeast. Molecular and Cellular Biology : 1720-1720	
C20	J. Histochem. Cytochem. (1995). 43, 77	
C21	Lidberg et al. (1998). Transcriptional Regulation of Human Carboxyl Ester Lipase Gene in Exocrine Pancreas. The Journal of Biological Chemistry 273: 47	
C22	Meyers and Miller (1988). Computer Applic. Biol. Sci. 4: 11-17	
C23	Miller et al. (1989). Biotechniques 7: 980-990	
C24	Needleman and Wunsch (1970). J. Mol. Biol. 48: 443	
C25	Ormerod (1994). Flow Cytometry : a practical approach. Second edition, IRL Press	
C26	Paulus et al. (1996). Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J. of Virology 70: 62-67	
C27	Pearson and Lipman (1988). Proc. Natl. Acad. Sci. 85: 2444	
C28	Person et al. (1994). Methods in Molecular Biology 24: 307-331	
C29	Persing et al. (1993). Diagnostic Molecular Microbiology: Principles and Applications. American Society for Microbiology, Washington, D.C.	
C30	Post et al. (1981). Cell 24: 555-565	
C31	Robinson (1993). Handbook of Flow Cytometry Methods. Wiley-Liss.	
C32	Robinson (2000). Current protocols in cytometry. John Wiley & Sons	
C33	Smith and Waterman (1981). Adv. Appl. Math. 2: 482	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/811,824
		Filing Date	March 19, 2003
		First Named Inventor	Charles Link
		Group Art Unit	1636
		Examiner Name	David A. Lambertson
		Attorney Docket Number	05237.0003.000000
Sheet	4	of	5


C34	Shapiro et al. (1998) Practical Flow Cytometry , Third Edition, Wiley-Liss	
C35	Shimatake et al. (1981). Nature 292: 128	
C36	Igarashi et. al. (1998). A Novel Strategy of Cell Targeting Based on Tissue-Specific Expression of the Ecotopic Retrovirus Expression Gene. Human Gene Therapy 9: 2691-2698	
C37	Valerie et al. (1998). Tissue Specific Cell Cycle Regulated Chimeric Transcription Factors for the Targeting of Gene Expression to Tumor Cells. Human Gene Therapy 9: 2653-2659	
C38	Medico et al (2001). A gene trap vector system for identifying transcriptionally responsive genes. Nature Biotech. 19: 579.	
C39	Wooten and Federhen (1993). Comput. Chem. 17: 149-163	
C40	Young and Link (2000). Chimeric Retroviral Helper Virus and Picornavirus IRES Sequence to Eliminate DNA Methylation for Improved Retroviral Packaging Cells. J. Virol. 74(11): 5242-5249	
C41	Young et al. (2000). DNA Methylation of Helper Virus Increases Genetic Instability of Retroviral Vector Produce Cells. J. Virol. 74(7): 3177-3187	
C42	Yu et al (1998). Coregulation of Tissue-Specific Alternative Human Carnitine Palmitoyltransferase IB Gene Promoter by Fatty Acid Enzyme Substrate. The Journal of Biological Chemistry 273, No. 49	
C43	Whitney et al (1998) A genome-wide functional assay of signal transduction in living mammalian cells. Nature Biotechnology 16:1329	
C44	Jarvik et al (1996). CD-Tagging: A new approach to gene and protein discovery and analysis. BioTechniques 20: 896-904	
C45	Skarnes et al (1995) Capturing genes encoding membrane and secreted proteins important for mouse development. Proc. Natl. Acad. Sci USA 92: 6592	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/811,824
				Filing Date	March 19, 2003
				First Named Inventor	Charles Link
				Group Art Unit	1636
				Examiner Name	David A. Lambertson
Sheet	5	of	5	Attorney Docket Number	05237.0003.000000

	C46	Zambrowicz et al (1998) Disruption and sequence identification of 2000 genes in mouse embryonic stem cells. Nature 392: 608-611.	
--	-----	--	--

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.